Phospho-ARAF (S299) Antibody

What is Phospho-ARAF (S299) Antibody and its molecular target?

Phospho-ARAF (S299) Antibody is a specialized antibody that detects endogenous levels of ARAF protein only when phosphorylated at the Serine 299 residue. ARAF is a proto-oncogene belonging to the RAF subfamily of Ser/Thr protein kinases with a calculated molecular weight of approximately 67-68 kDa . This antibody recognizes phosphorylation at a specific site (S299) which is crucial for understanding ARAF activation in signaling cascades . The antibody is typically raised in rabbits using synthetic phosphorylated peptides derived from the region surrounding S299 of human ARAF (NP_001645.1) as immunogens .

What biological roles does ARAF play in cellular signaling?

ARAF functions as an intermediate in signal transduction pathways alongside other kinases like ERK/MAP kinases and ribosomal S6 kinase (Rsk) . As a member of the RAF family, ARAF is involved in:

• Cell growth and development regulation

• Signal transduction pathways downstream of growth factor receptors

• Potential roles in cardiac function and hypertrophy

• Possible involvement in podocyte protection mechanisms

Research indicates that ARAF is activated in cardiomyocytes by growth factors and hypertrophic agonists such as endothelin-1, suggesting tissue-specific functions . Expression patterns show highest levels in urogenital tissues and kidney with lowest expression in brain tissue .

What applications is the Phospho-ARAF (S299) antibody validated for?

Based on validation data from multiple sources, the antibody is confirmed for:

Researchers should note that application validation varies between manufacturers, with some antibodies tested more extensively than others .

How should researchers optimize storage conditions for Phospho-ARAF (S299) antibodies?

For optimal antibody performance and longevity, follow these evidence-based storage recommendations:

• Short-term storage (up to one month): 4°C is acceptable for frequent use

• Long-term storage: -20°C or below in aliquots

• Avoid repeated freeze-thaw cycles which degrade antibody quality

• Most formulations contain 50% glycerol, which helps prevent freezing damage

• Some preparations include stabilizers such as 0.5% BSA and 0.02% sodium azide

For reconstituted lyophilized antibodies, maintain sterility and follow manufacturer-specific guidelines for buffer compositions, as these can affect stability and performance in different applications .

What are the recommended protocols for detecting phospho-ARAF (S299) in different sample types?

Detection protocols should be optimized based on sample type and experimental goals:

For Western Blot:

• Sample preparation: Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

• Recommended dilution: 1:1000-1:2000 in 5% BSA/TBST buffer

• Detection systems: Both chemiluminescence and fluorescence-based systems are suitable

• Expected molecular weight observation: 67kDa (though some sources report 20kDa/67kDa)

For Immunohistochemistry:

• Fixation: Paraformaldehyde or formalin fixation works well

• Antigen retrieval: Heat-mediated retrieval in citrate buffer is typically required

• Dilution range: 1:100-1:300

• Detection: Indirect detection systems using biotin-streptavidin or polymer-based methods show good results

For ELISA:

• Coating concentration optimization is critical

• Recommended dilution: 1:5000

• Standard curves using recombinant proteins can help quantify results

How can researchers validate antibody specificity for phospho-ARAF (S299)?

To ensure experimental rigor, implement these validation approaches:

• Peptide competition assay: Use the synthetic phosphorylated peptide immunogen to block antibody binding, which should eliminate specific signals

• Phosphatase treatment: Treat one sample with lambda phosphatase to remove phosphorylation, which should eliminate signal compared to untreated controls

• siRNA knockdown: Reduce ARAF expression through siRNA and observe corresponding reduction in phospho-signal

• Cross-reactivity testing: Evaluate against related RAF family members (BRAF, CRAF) to ensure specificity

• Positive controls: Use samples known to contain phosphorylated ARAF (S299), such as cells treated with growth factors that activate the RAF pathway

• Western blot analysis: Verify single band at expected molecular weight (approximately 67kDa)

How should researchers interpret changes in ARAF phosphorylation at S299 in experimental systems?

The interpretation of ARAF phosphorylation dynamics requires consideration of multiple factors:

• Baseline vs. stimulated conditions: Establish baseline phosphorylation levels in your specific cell types/tissues before interpreting changes

• Temporal dynamics: ARAF phosphorylation may show rapid and transient patterns following stimulation, necessitating time-course studies

• Context within RAF family: Consider parallel assessment of BRAF and CRAF phosphorylation to understand isoform-specific activation patterns. Research indicates ARAF may have distinct functions from other RAF proteins in certain contexts

• Downstream effects: Correlate ARAF phosphorylation with activation of downstream targets (particularly ERK1/2) to establish functional relevance

• Stimulus specificity: Different stimuli may induce variable patterns of ARAF phosphorylation. For example, in podocytes, GDC-0879 may act through both BRAF and ARAF

What are common troubleshooting approaches for inconsistent phospho-ARAF (S299) detection?

When facing detection challenges, consider these methodological solutions:

• High background issues:

  • Increase blocking concentration (5% BSA or milk)

  • Optimize antibody dilution (try higher dilutions)

  • Use longer/more thorough washing steps

  • Consider specialized blocking reagents for problematic samples

• Weak or absent signal:

  • Ensure phosphorylation preservation through immediate sample processing

  • Use fresh phosphatase inhibitor cocktails in all buffers

  • Try signal enhancement systems

  • Increase protein loading (for Western blots)

  • Optimize antigen retrieval methods (for IHC)

• Multiple bands or unexpected molecular weights:

  • Verify sample integrity (potential degradation)

  • Consider alternative splice variants (ARAF has known alternatively spliced variants)

  • Check for post-translational modifications affecting migration

  • Use more stringent washing conditions to reduce non-specific binding

• Inconsistent results between experiments:

  • Standardize lysate preparation protocols

  • Use internal loading controls consistently

  • Prepare larger batches of working antibody dilutions

  • Consider lot-to-lot variations in antibodies

How does ARAF phosphorylation at S299 relate to the "RAF paradox" observed with RAF inhibitors?

The "RAF paradox" refers to the seemingly contradictory effect where RAF inhibitors can activate rather than inhibit RAF signaling under certain conditions. For ARAF specifically:

• Type 1 RAF inhibitors like SB590885 and encorafenib have been shown to increase ERK1/2 phosphorylation in cardiomyocytes, promoting hypertrophy through this paradoxical activation

• Studies found that RAF inhibitors can promote cardiac hypertrophy in mouse hearts in vivo, increasing cardiomyocyte size without causing fibrosis

• The mechanistic relationship between S299 phosphorylation specifically and this paradox remains an active research area. Current evidence suggests RAF inhibitors may differentially affect ARAF, BRAF, and CRAF phosphorylation states leading to altered dimer formation and downstream signaling

Researchers investigating this phenomenon should consider:

• Examining multiple phosphorylation sites on ARAF beyond S299

• Analyzing dimerization patterns following inhibitor treatment

• Monitoring activation of multiple downstream pathways beyond ERK1/2

What experimental systems are optimal for studying ARAF phosphorylation in disease models?

When designing experiments to investigate ARAF phosphorylation in disease contexts, consider:

Cardiac Research Models:

• Cardiomyocyte cultures respond to growth factors and hypertrophic agonists with ARAF activation

• In vivo cardiac hypertrophy models show distinct ARAF phosphorylation patterns

• BRAF inhibitors can be used as experimental tools to modulate cardiac hypertrophy through effects that may involve ARAF

Kidney Research Models:

• Podocyte cell cultures under ER stress conditions can help examine ARAF's role in cell protection mechanisms

• GDC-0879 (BRAF inhibitor) shows protection in these models potentially through ARAF

Cancer Research Applications:

• Cell line panels with varying RAF mutation status can help distinguish ARAF-specific functions

• Patient-derived xenografts may provide clinically relevant models for studying ARAF phosphorylation

• Conditional expression systems allow temporal control of ARAF activity

When designing these experiments, researchers should incorporate:

• Appropriate controls for phosphorylation status

• Time-course analyses to capture transient phosphorylation events

• Multiple detection methods to confirm results (e.g., Western blot plus immunofluorescence)

• Functional readouts to correlate phosphorylation with biological outcomes

What is the significance of ARAF S299 phosphorylation compared to other phosphorylation sites on ARAF?

ARAF contains multiple phosphorylation sites that regulate its activity and interactions. S299 phosphorylation:

• Occurs within a region that may influence kinase activity and substrate recognition

• Has been studied less extensively than some other RAF family phosphorylation sites

• May have different regulatory functions than equivalent sites in BRAF or CRAF

• Could serve as a biomarker for specific activation states in different tissues

Research suggests that phosphorylation patterns across multiple sites collectively determine ARAF's functional state. When investigating S299 phosphorylation specifically, consider:

• Examining co-occurrence with other phosphorylation events

• Identifying kinases responsible for S299 phosphorylation under different conditions

• Determining whether S299 phosphorylation is necessary and/or sufficient for ARAF activation

• Exploring tissue-specific patterns of S299 phosphorylation, particularly in urogenital tissues and kidney where ARAF expression is highest

How can researchers effectively use phospho-ARAF (S299) antibodies in multi-parameter analyses?

For complex, multi-parameter studies incorporating phospho-ARAF (S299) detection:

Multiplex Immunofluorescence:

• Compatible with co-staining for other RAF family members

• Can be combined with markers of cellular compartments to determine localization

• Works effectively with phospho-ERK1/2 antibodies to correlate ARAF activation with downstream effects

Flow Cytometry Applications:

• Requires optimization of fixation and permeabilization protocols

• Can be combined with cell cycle markers or apoptosis indicators

• Allows quantitative assessment of phospho-ARAF levels at single-cell resolution

Mass Cytometry (CyTOF):

• Enables highly multiplexed detection of multiple phosphorylation sites

• Requires metal-conjugated antibodies

• Provides unprecedented resolution of signaling network activities

Phosphoproteomics Integration:

• Antibody-based enrichment of ARAF can be followed by mass spectrometry

• Allows detection of multiple phosphorylation sites simultaneously

• Can reveal previously unknown modification patterns and their relationships

When designing multi-parameter analyses, careful validation of antibody specificity in the specific experimental context is critical to avoid artifacts from antibody cross-reactivity or non-specific binding.

How does ARAF phosphorylation contribute to cardiac hypertrophy mechanisms?

Research indicates specific roles for ARAF phosphorylation in cardiac function:

• RAF1 and ARAF are activated in cardiomyocytes by growth factors and hypertrophic agonists like endothelin-1

• Type 1 RAF inhibitors (SB590885 and encorafenib) increase ERK1/2 phosphorylation in cardiomyocytes and promote hypertrophy through the "RAF paradox" effect

• In mouse models, these inhibitors promoted cardiac hypertrophy in vivo, characterized by increased cardiomyocyte size without significant fibrosis

• This suggests ARAF phosphorylation status may be a key determinant in compensated cardiac hypertrophy rather than pathological hypertrophy

When studying ARAF in cardiac models, researchers should consider:

• Temporal dynamics of phosphorylation after hypertrophic stimuli

• Differential effects on cardiac function parameters

• Potential therapeutic applications for modulating ARAF phosphorylation

What methodological approaches help distinguish ARAF functions from other RAF family members?

Distinguishing ARAF-specific functions requires specialized experimental designs:

• Isoform-specific knockdown/knockout models:

  • siRNA targeting ARAF specifically

  • CRISPR/Cas9 genome editing of ARAF

  • Conditional knockout models for tissue-specific ARAF deletion

• Pharmacological approaches:

  • Identifying compounds with preferential activity toward ARAF vs BRAF/CRAF

  • Using the GDC-0879 BRAF inhibitor, which research suggests may act through both BRAF and ARAF (but not CRAF) in some contexts

• Rescue experiments:

  • Re-expression of wild-type vs. S299A mutant ARAF in knockout backgrounds

  • Creation of phosphomimetic mutations (S299D/E) to simulate constitutive phosphorylation

• Biochemical interaction studies:

  • Immunoprecipitation with phospho-specific antibodies to identify differential binding partners

  • Protein-protein interaction mapping under different phosphorylation states